Table of Content

1 INTRODUCTION (Page No. - 20)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED IN THE REPORT
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 24)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
           FIGURE 2 PRIMARY SOURCES
           FIGURE 3 PDX MODEL MARKET: BREAKDOWN OF PRIMARIES
                    2.1.2.1 Key industry insights
    2.2 MARKET SIZE ESTIMATION
           FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS, 2020
           FIGURE 5 AVERAGE MARKET SIZE ESTIMATION, 2020
           FIGURE 6 MARKET: CAGR PROJECTIONS, 2021–2026
           FIGURE 7 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS
    2.5 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 34)
           FIGURE 9 PDX MODEL MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
           FIGURE 10 MARKET, BY TUMOR TYPE, 2021 VS. 2026 (USD MILLION)
           FIGURE 11 MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
           FIGURE 12 MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
           FIGURE 13 MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS (Page No. - 38)
    4.1 PDX MODEL MARKET OVERVIEW
           FIGURE 14 INCREASING SUPPORT FOR CANCER RESEARCH FROM PUBLIC AND PRIVATE SECTORS AND GROWING DEMAND FOR PRECISION MEDICINE ARE KEY GROWTH DRIVERS
    4.2 NORTH AMERICA: MARKET, MARKET SHARE (2020)
           FIGURE 15 MICE MODELS COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
    4.3 MARKET SHARE, BY END USER (2020)
           FIGURE 16 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES COMMANDED THE LARGEST SHARE OF THE MARKET IN 2020
    4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 17 CHINA TO WITNESS THE HIGHEST GROWTH IN THE MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 41)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 18 PDX MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           TABLE 1 PDX MODEL INDUSTRY: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Growing demand for personalized medicine
                    5.2.1.2 Continuous support for cancer research from the public & private sectors
                    5.2.1.3 Rising pharma R&D
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of personalized PDX models
                    5.2.2.2 Stringent guidelines for the use of animal models in cancer research
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Rising demand for humanized PDX models
           5.2.4 CHALLENGES
                    5.2.4.1 Limitations of PDX models
    5.3 IMPACT OF THE COVID-19 OUTBREAK ON THE GROWTH OF THE MARKET
    5.4 TECHNOLOGICAL ANALYSIS
    5.5 PRICING ANALYSIS
    5.6 VALUE CHAIN ANALYSIS
           FIGURE 19 VALUE CHAIN ANALYSIS OF MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE
           FIGURE 20 VALUE CHAIN: CREATION OF PDX MODELS—MAXIMUM VALUE IS ADDED DURING THE IMPLANTATIONS OF TUMOR CELLS IN IMMUNODEFICIENT MICE OR RATS
    5.7 ECOSYSTEM ANALYSIS OF THE MARKET
           FIGURE 21 ECOSYSTEM ANALYSIS OF THE MARKET
           TABLE 2 SUPPLY CHAIN ECOSYSTEM
    5.8 PORTER’S FIVE FORCES ANALYSIS
           TABLE 3 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 THREAT OF SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 INTENSITY OF COMPETITIVE RIVALRY
    5.9 REGULATORY ANALYSIS
           5.9.1 NORTH AMERICA
           5.9.2 EUROPE
           5.9.3 ASIA PACIFIC
                    5.9.3.1 China
                    5.9.3.2 Japan
                    5.9.3.3 India
                    5.9.3.4 Australia
           5.9.4 LATIN AMERICA
           5.9.5 MIDDLE EAST & AFRICA
    5.10 PATENT ANALYSIS
           FIGURE 22 PATENTS GRANTED FOR PDX MODELS, JANUARY 2010–DECEMBER 2020

6 PDX MODEL MARKET, BY TYPE (Page No. - 59)
    6.1 INTRODUCTION
           TABLE 4 PDX MODEL INDUSTRY, BY TYPE, 2019–2026 (USD MILLION)
    6.2 MICE MODELS
           6.2.1 EASE OF PROCUREMENT AND WIDE AVAILABILITY OF MICE MODELS DRIVE THE GROWTH OF THIS SEGMENT
           TABLE 5 PDX MICE MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 6 NORTH AMERICA: PDX MICE MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 7 EUROPE: PDX MICE MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 8 ASIA PACIFIC: PDX MICE MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3 RAT MODELS
           6.3.1 FACTORS SUCH AS EASIER SURGICAL MANIPULATION AND LARGER TUMOR SIZE WILL SUPPORT USE OF RAT MODELS
           TABLE 9 PDX RAT MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 10 NORTH AMERICA: PDX RAT MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 11 EUROPE: PDX RAT MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 12 ASIA PACIFIC: PDX RAT MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7 PDX MODEL MARKET, BY TUMOR TYPE (Page No. - 64)
    7.1 INTRODUCTION
           TABLE 13 PDX MODEL INDUSTRY, BY TUMOR TYPE, 2019–2026 (USD MILLION)
    7.2 GASTROINTESTINAL TUMOR MODELS
           7.2.1 NEWLY DEVELOPED GASTROINTESTINAL TUMOR MODELS MIMIC THE TUMOR BETTER THAN PREVIOUS MODELS
           TABLE 14 GASTROINTESTINAL TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 15 NORTH AMERICA: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 16 EUROPE: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 17 ASIA PACIFIC: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 GYNECOLOGICAL TUMOR MODELS
           7.3.1 HIGH INCIDENCE OF TARGET CANCERS HAS DRIVEN DEMAND FOR TUMOR MODELS
           TABLE 18 GYNECOLOGICAL TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 19 NORTH AMERICA: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 20 EUROPE: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 21 ASIA PACIFIC: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.4 RESPIRATORY TUMOR MODELS
           7.4.1 RISING PREVALENCE OF LUNG CANCER TO DRIVE MARKET GROWTH
           TABLE 22 RESPIRATORY TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 23 NORTH AMERICA: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 24 EUROPE: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 25 ASIA PACIFIC: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.5 UROLOGICAL TUMOR MODELS
           7.5.1 COMPANIES ARE FOCUSING ON EXPANDING THEIR PORTFOLIO FOR UROLOGICAL CANCERS
           TABLE 26 UROLOGICAL TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 27 NORTH AMERICA: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 28 EUROPE: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 29 ASIA PACIFIC: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.6 HEMATOLOGICAL TUMOR MODELS
           7.6.1 NEW STRAINS SUCH AS NSG AND NOG HAVE INCREASED THE LIFE SPAN OF HEMATOLOGICAL TUMOR MODELS
           TABLE 30 HEMATOLOGICAL TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 31 NORTH AMERICA: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 32 EUROPE: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 33 ASIA PACIFIC: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.7 OTHER TUMOR MODELS
           TABLE 34 OTHER TUMOR MODELS MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 35 NORTH AMERICA: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 36 EUROPE: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 37 ASIA PACIFIC: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 PDX MODEL MARKET, BY APPLICATION (Page No. - 76)
    8.1 INTRODUCTION
           TABLE 38 PDX MODEL INDUSTRY, BY APPLICATION, 2021–2026 (USD MILLION)
    8.2 PRECLINICAL DRUG DEVELOPMENT
           8.2.1 RISE IN NUMBER OF CLINICAL TRIALS WILL DRIVE THE GROWTH OF THIS SEGMENT
           TABLE 39 MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2019–2026 (USD MILLION)
           TABLE 40 NORTH AMERICA: MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 41 EUROPE: MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 42 ASIA PACIFIC: MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 BIOMARKER ANALYSIS
           8.3.1 GROWING INTEREST IN PRECISION MEDICINE WILL CONTRIBUTE TO THE DEMAND FOR PDX MODELS FOR BIOMARKER ANALYSIS
           TABLE 43 MARKET FOR BIOMARKER ANALYSIS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 44 NORTH AMERICA: MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 45 EUROPE: MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 46 ASIA PACIFIC: MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 BASIC CANCER RESEARCH
           8.4.1 RISING FUNDING FOR CANCER RESEARCH WILL DRIVE MARKET GROWTH IN THIS SEGMENT
           TABLE 47 MARKET FOR BASIC CANCER RESEARCH, BY REGION, 2019–2026 (USD MILLION)
           TABLE 48 NORTH AMERICA: MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 49 EUROPE: MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 50 ASIA PACIFIC: MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019–2026 (USD MILLION)

9 PDX MODEL MARKET, BY END USER (Page No. - 84)
    9.1 INTRODUCTION
           TABLE 51 PDX MODEL INDUSTRY, BY END USER, 2019–2026 (USD MILLION)
    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
           9.2.1 RISING COLLABORATION BETWEEN PHARMA & BIOTECH COMPANIES FOR DEVELOPING CANCER THERAPEUTICS
           TABLE 52 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
           TABLE 53 NORTH AMERICA: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 54 EUROPE: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 55 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 CONTRACT RESEARCH ORGANIZATIONS
           9.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES WILL DRIVE MARKET GROWTH
           TABLE 56 MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 57 NORTH AMERICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 58 EUROPE: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 59 ASIA PACIFIC: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 ACADEMIC & RESEARCH INSTITUTIONS
           9.4.1 INCREASE IN GOVERNMENT LIFE SCIENCES R&D EXPENDITURE WILL CONTRIBUTE TO THE GROWTH OF THIS SEGMENT
           TABLE 60 MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 61 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 62 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 63 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019–2026 (USD MILLION)

10 PDX MODEL MARKET, BY REGION (Page No. - 92)
     10.2 NORTH AMERICA
           TABLE 64 PDX MODEL INDUSTRY, BY REGION, 2019–2026 (USD MILLION)
     10.2 NORTH AMERICA
           FIGURE 23 NORTH AMERICA: PDX MODEL MARKET SNAPSHOT
           TABLE 65 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 66 NORTH AMERICA: MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 67 NORTH AMERICA: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 68 NORTH AMERICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 69 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Growing focus on cancer research in the US will drive market growth
           TABLE 70 US: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 71 US: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 72 US: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 73 US: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Growth in Canada can be attributed to rising funding for stem cell research in the country
           TABLE 74 CANADA: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 75 CANADA: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 76 CANADA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 77 CANADA: MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.3 EUROPE
           TABLE 78 EUROPE: PDX MODEL MARKET, BY COUNTRY/REGION, 2019–2026 (USD MILLION)
           TABLE 79 EUROPE: MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 80 EUROPE: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 81 EUROPE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 82 EUROPE: PDX MODEL INDUSTRY, BY END USER, 2019–2026 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Government funding for life science R&D and basic cancer research will drive market growth
           TABLE 83 GERMANY: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 84 GERMANY: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 85 GERMANY: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 86 GERMANY: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 The rising incidence of cancer cases will lead to an increase in cancer research, which will drive market growth
           TABLE 87 UK: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 88 UK: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 89 UK: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 90 UK: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Increasing government funding for cancer research
           TABLE 91 FRANCE: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 92 FRANCE: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 93 FRANCE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 94 FRANCE: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.4 ROE
           TABLE 95 ROE: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 96 ROE: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 97 ROE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 98 ROE: PDX MODEL INDUSTRY, BY END USER, 2019–2026 (USD MILLION)
     10.4 ASIA PACIFIC
           FIGURE 24 ASIA PACIFIC: PDX MODEL MARKET SNAPSHOT
           TABLE 99 ASIA PACIFIC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 100 ASIA PACIFIC: MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 101 ASIA PACIFIC: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 102 ASIA PACIFIC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 103 ASIA PACIFIC: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 The growing pharmaceutical industry and rising number of CROs in the country will drive market growth
           TABLE 104 CHINA: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 105 CHINA: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 106 CHINA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 107 CHINA: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Research collaborations and growing geriatric population—key growth drivers in Japan
           TABLE 108 JAPAN: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 109 JAPAN: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 110 JAPAN: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 111 JAPAN: MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.3 REST OF ASIA PACIFIC
           TABLE 112 ROAPAC: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 113 ROAPAC: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 114 ROAPAC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 115 ROAPAC: PDX MODEL INDUSTRY, BY END USER, 2019–2026 (USD MILLION)
     10.5 LATIN AMERICA
             10.5.1 RISING PHARMACEUTICAL R&D EXPENDITURE IN THE REGION WILL DRIVE THE GROWTH OF THE MARKET
           TABLE 116 LATIN AMERICA: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 117 LATIN AMERICA: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 118 LATIN AMERICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 119 LATIN AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 MARKET GROWTH DRIVEN BY CHANGING DEMOGRAPHICS AND FAVORABLE POLICIES FOR PHARMA R&D
           TABLE 120 MIDDLE EAST AND AFRICA: PDX MODEL MARKET, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 121 MIDDLE EAST AND AFRICA: MARKET, BY TUMOR TYPE, 2019–2026 (USD MILLION)
           TABLE 122 MIDDLE EAST AND AFRICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 123 MIDDLE EAST AND AFRICA: MARKET, BY END USER, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 122)
     11.1 OVERVIEW
     11.2 MARKET EVALUATION FRAMEWORK
           TABLE 124 MARKET EVALUATION FRAMEWORK: PARTNERSHIPS, AGREEMENTS, JOINT VENTURES, AND COLLABORATIONS—THE MAJOR STRATEGIES ADOPTED BY PLAYERS
     11.3 MARKET SHARE ANALYSIS
           FIGURE 25 PDX MODEL MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
     11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
           FIGURE 26 TOP MARKET PLAYERS DOMINATE THE PDX MODEL INDUSTRY
     11.5 COMPANY EVALUATION QUADRANT
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE
             11.5.4 EMERGING COMPANIES
           FIGURE 27 MARKET: COMPANY EVALUATION QUADRANT, 2020
     11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
           FIGURE 28 MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
     11.7 COMPANY PRODUCT FOOTPRINT
           TABLE 125 PRODUCT PORTFOLIO ANALYSIS: MARKET (2020)
     11.8 COMPANY GEOGRAPHIC FOOTPRINT
           TABLE 126 GEOGRAPHIC REVENUE MIX: MARKET (2020)
     11.9 COMPETITIVE SCENARIO
             11.9.1 MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2018–FEBRUARY 2021
             11.9.2 PDX MODEL INDUSTRY: DEALS, JANUARY 2019–FEBRUARY 2021
             11.9.3 PDX MODEL MARKET: OTHER DEVELOPMENTS, JANUARY 2018–FEBRUARY 2021

12 COMPANY PROFILES (Page No. - 133)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)* 
     12.1 KEY MARKET PLAYERS
             12.1.1 JSR CORPORATION
           FIGURE 29 JSR CORPORATION: COMPANY SNAPSHOT (2019)
             12.1.2 WUXI APPTEC
           FIGURE 30 WUXI APPTEC: COMPANY SNAPSHOT (2020)
             12.1.3 THE JACKSON LABORATORY
           FIGURE 31 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2019)
             12.1.4 CHARLES RIVER LABORATORIES
           FIGURE 32 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020)
             12.1.5 CHAMPIONS ONCOLOGY
           FIGURE 33 CHAMPIONS ONCOLOGY: COMPANY SNAPSHOT (2020)
             12.1.6 ONCODESIGN
           FIGURE 34 ONCODESIGN: COMPANY SNAPSHOT (2020)
             12.1.7 ENVIGO
             12.1.8 PHARMATEST SERVICES
             12.1.9 HERA BIOLABS
             12.1.10 EPO BERLIN-BUCH GMBH
             12.1.11 XENTECH
             12.1.12 UROSPHERE
     12.2 OTHER PLAYERS
             12.2.1 ABNOVA CORPORATION
             12.2.2 GENESIS BIOTECHNOLOGY GROUP
             12.2.3 EXPLORA BIOLABS
             12.2.4 BIOCYTOGEN
             12.2.5 LIVING TUMOR LABORATORY
             12.2.6 BIODURO
             12.2.7 ARAGEN LIFE SCIENCES W.E.F
             12.2.8 SHANGHAI LIDE BIOTECH
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies. 

13 APPENDIX (Page No. - 166)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS